Paratek Pharmaceuticals, Inc.
PRTKDelisted Sep 21, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178711
Paratek Pharmaceuticals, Inc. was delisted on Sep 21, 2023; its insiders filed their last Form 4 on Sep 21, 2023; 66 institutions reported holding it in 13F filings for Q2 2023, worth $47.0M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 66
- Q2 2023, +4 vs. previous quarter
- 13F value
- $47.0M
- Reported value at the end of Q2 2023
- Superinvestors holding
- 0
- At the end of Q2 2023
Superinvestors holding PRTK, Q2 2023
No superinvestor reported holding PRTK at the end of Q2 2023.
Latest insider trades
Open-market purchases and sales by Paratek Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2023 (view filing) | Aug 9 | 1 day | Brenner Randall B.Chief Development & Regulatory | SSale | −27.6K | $2.20 | −$60.7K | −6.2%415.2K after | 10b5-1 |
| Aug 10, 2023 (view filing) | Aug 9 | 1 day | Bigham MichaelExec. Chairman of the Board | SSale | −31.3K | $2.20 | −$68.8K | −2.3%1.33M after | 10b5-1 |
| Aug 10, 2023 (view filing) | Aug 9 | 1 day | Haskel William M.CLO, General Counsel & Sec. | SSale | −34.5K | $2.20 | −$76.0K | −7.2%447.0K after | 10b5-1 |
| Aug 10, 2023 (view filing) | Aug 9 | 1 day | Loh EvanCEO | SSale | −49.0K | $2.20 | −$107.7K | −3.6%1.33M after | |
| Mar 29, 2023 (view filing) | Mar 17-23 | 12 daysLate | Dondero James D10% Owner | PPurchase | +788.5K | $1.63 | +$1.28M | +57.7%2.16M after | 5 lots |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Stein JeffreyDirector | SSale | −7.00K | $1.90 | −$13.3K | −9.3%68.6K after | |
| Feb 23, 2023 (view filing) | Feb 21 | 2 days | Franson Timothy RDirector | SSale | −7.00K | $1.88 | −$13.2K | −8.9%72.0K after | |
| Dec 22, 2022 (view filing) | Dec 21 | 1 day | Woodrow AdamPresident & Chief Commercial | SSale | −6.75K | $1.99 | −$13.4K | −1.0%651.3K after | |
| Dec 22, 2022 (view filing) | Dec 21 | 1 day | Loh EvanCEO | SSale | −23.5K | $1.99 | −$46.7K | −1.9%1.21M after | |
| Dec 22, 2022 (view filing) | Dec 21 | 1 day | Haskel William M.CLO, General Counsel & Sec. | SSale | −7.01K | $1.99 | −$13.9K | −1.7%407.8K after |
Top 10 13F holders, Q2 2023
The largest institutional positions in Paratek Pharmaceuticals, Inc. at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Highland Capital Management Fund Advisors, L.P. | 2,495,770 | $5.52M | 0.83% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,228,066 | $4.92M | 0.00% | 00.0% | Unchanged |
| General American Investors Co Inc | 1,839,424 | $4.07M | 0.35% | −75,000−3.9% | Reduced |
| Rock Springs Capital Management LP | 1,734,037 | $3.83M | 0.09% | 00.0% | Unchanged |
| Bruce & Co., Inc. | 1,556,247 | $3.44M | 0.96% | 00.0% | Unchanged |
| Eversept Partners, LP | 1,327,857 | $2.93M | 0.31% | +689,383+108.0% | Added |
| Carlyle Group Inc. | 1,041,131 | $2.30M | 0.08% | 00.0% | Unchanged |
| BlackRock Inc. | 894,894 | $1.98M | 0.00% | −172,117−16.1% | Reduced |
| Newtyn Management, LLC | 764,274 | $1.69M | 0.40% | +764,274 | New |
| J. Goldman & Co LP | 758,431 | $1.68M | 0.10% | −157,070−17.2% | Reduced |